HER2 drugs for HER2-Positive Breast Cancer
9 tracked HER2 drugs in the HER2-Positive Breast Cancer race. The class explanation lives on the HER2 page; the full indication pipeline across every mechanism is on the HER2-Positive Breast Cancer page.
3 approved / phase 44 Phase 32 Phase 2/3
Head-to-head evidence: Bizrolertinib vs Disitamab Vedotin · Bizrolertinib vs Trastuzumab Deruxtecan · Bizrolertinib vs Trastuzumab pamirtecan · Bizrolertinib vs Tucatinib · Disitamab Vedotin vs Trastuzumab Deruxtecan · Disitamab Vedotin vs Trastuzumab brengitecan